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We have studied the in vivo effects of recombinant human interleukin-6 (rhlL-6) on hematopoiesis in eight healthy and nine irradiated cynomolgus monkeys. Of the healthy animals, three received rhlL-6 alone (10 pg/kg/d. subcutaneously [SC] ), one received rhlL-6 in combination with rhlL-3 (10 pg/kg/d, SC), one received rhlL-6 in combination with recombinant cynomolgus granulocyte-macrophage colonystimulating factor (rcGM-CSF; 10 pg/kg/d, SC), two received rhlL-6 iri combination with recombinant human granulocyte-CSF (rhG-CSF; 10 pg/kg/d, SC), and one received rhlL-6 in combination with recombinant human lehkemia inhibitory factor (rhLIF; 10 pg/kg/d, SC). All animals were treated for at least 2 weeks with rhlL-6 or the above mentioned combinations. rhlL-6 alone significantly increased the peripheral blood platelet counts (2-t o 3.5-fold). The platelets reached a plateau between days 10 and 15 of treatment. No synergistic effects on platelet numbers were observed when rhlL-6 was combined with rhlL-3, rcGM-CSF, rhG-CSF, or rhLIF. In addition t o rhlL-6, only rhLlF increased NTERLEUKIN-6 (IL-6) demonstrates various biologic I activities in vitro on B lymphocytes,' T lymphocytes,* plasmocytoma^,^ hepatocyte^,^ and hematopoietic cells.5-8 IL-6 has been shown to act as a synergistic factor in combination with IL-3 on early myeloid and megakaryocytic progenitor cell^.^,^ Recently, several investigators have reported that IL-6 administered in vivo induced platelet increases in mice9-" and primates.'*J3 Leukemia inhibitory factor (LIF) has also been shown to exhibit pleiotropic activities, including suppression of proliferation of the murine leukemic cell line M1, inhibition of spontaneous differentiation of embryonic stem cells, stimulation of hepatocytes, differentiation of neuronal cells, release of calcium from bone, and increases in platelets in mice.I4 The in vitro and in vivo activities of recombinant human IL-3 (rhIL-3), recombinant cynomolgus granulocyte-macrophage colony-stimulating factor (rcGM-CSF), and recombinant human granulocyte-CSF (rhG-CSF) have been well documented.15J6 To investigate the in vivo biologic activity of rhIL-6 in combination with rhIL-3, rcGM-CSF, rhG-the platelet numbers when administered alone. To test whether rhlL-6 might also protect the animal from thrombocytopenia or shorten the time of thrombocytopenia after irradiation, we treated nine animals with total body irradiation (3.8 Gy). Six of the animals were additional treated with rhlL-6 (4 with 10 pg/ kg/d; and 2 with 100 pC/ kg/d) from day -1 or +1 t o day 28 post irradiation. In these animals, rhlL-6 at the same dose effective in healthy animals (10 pg/kg/d) was not capable of protecting the animals from platelet nadir. However, when pegylated rhlL-6 was used at a dosage of 100 pg/kg/d post irradiation, the mean of the nadirs was 71,OOO/pL as compared with 39,00O/pL in control animals and the time of thrombocytopenia was shorter (3 Y 5 days). In all animals (healthy and irradiated), rhlL-6 did not increase the number of bone marrow megakaryocytes but induced a right shift of DNA ploidy in megakaryocytes. These data suggest that IL-6 acts as "thrombopoietin"4ike activity, but not as "megakaryocyte-CSF"-like activity.
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CSF, or rhLIF on the hematopoietic system, we selected the cynomolgus monkey as a model based on the similarities between the simian and human hematop~iesis.~~ We administered rhIL-6 alone or in combination with rhG-CSF, rcGM-CSF, rhIL-3, or rhLIF (10 pg/kg/d each) as daily subcutaneous (SC) injections over a varying time period. In addition, we investigated whether rhIL-6 could protect the animals from or shorten the period of thrombocytopenia after total body irradiation (TBI).
MATERIALS AND METHODS

Animals.
Juvenile healthy female or male cynomolgus monkeys (Macaque fasicularis) were obtained from Tierlaboratorium, Universitat Diisseldorf (Dusseldorf, Germany). They were maintained according to the German guidelines for the use and care of laboratory animals. Blood samples were taken by puncture of peripheral veins. Before all manipulations, animals were anesthetized with ketamine hydrochloride (Parke-Davis, Berlin, GennaHematologic counts were performed using a routine automated hematologic analyzer. Differential counts of leukocytes were performed on glass slides stained with May-Griinwald-Giemsa.
Bone marrow (BM) megakaryocytes. The number of BM megakaryocytes was determined by counting 5,000 mononuclear BM cells and calculating the number of megakaryocytes per 1,000 mononuclear cells on regular glass slides stained with MayGriinwald-Giemsa.
To study the DNA ploidy of megakaryocytic cells, megakaryocytes were enriched from BM aspirates by density gradient centrifugation, labeled simultaneously with anti-glycoprotein (antiGPIIIa) monoclonal antibodies (directly coupled with fluorescein isothiocyanate [FITC] ) and with propidium iodine (Pi), and analyzed by two-color flow cytometry (FACScan; Becton Dickinson, Mountain View, CA). Details about the composition of the aspiration medium as well as the separation and labeling procedures have been described p r e v i o~s l y .~~~'~ All recombinant factors used were expressed in Escherichia coli. The specific activities of rhG-CSF, rhIL-3, and rcGM-CSF were each approximately lo8 U/mg as nY).
Peripheral blood (PB) counts.
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assayed in colony-forming unit granulocyte-macrophage (CFU-GM) assays.zo rhIL-6 showed a specific activity of 2 x lo7 U/mg, as assessed by measuring IgM production from the human B-lymphoblastoid-cell line, SKW6-CL4.21 Pegylated rhIL-6 (Peg-rhIL-6) was prepared at Kirin Brewery Co (Tokyo, Japan) as follows. A succinimidyl succinate derivative of polyethylene glycol (PEG), methoxypolyethylene glycol succinate with an average molecular weight of 12,000 and coupled to N-hydroxysuccinimide, was obtained from Nippon Oil & Fats Co (Tokyo, Japan). The rhIL-6 was dissolved in 0.1 mol/L sodium borate buffer (pH 8.5) and activated PEG was added in a 10-fold concentration as compared with rhIL-6 to the solution in three additions at 30-minute intervals in an ice bath with stirring. The reaction mixture was concentrated with YMlO ultrafiltration membrane (Amicon) and was applied to a Superdex G200 column (Pharmacia, Uppsala, Sweden) equilibrated with phosphate-buffered saline (PBS). The Peg-rhIL-6 was eluted in several fractions and each fraction was characterized by determining the number of free amino groups. Briefly, the PegrhIL-6 was reacted with 7.5% fluorescamine in 0.1 mol/L sodium phosphate buffer (pH 8.0) and the number of free amino groups was determined by measuring the intensity of fluorescence at 475 nm (excited at 390 nm). The polypeptide in which approximately 50% of amino groups were pegylated was used as Peg-rhIL-6. All cytokines used were not pyrogenic, as tested in limulus amoebocyte lysate assays.
Three monkeys received rhIL-6 alone (10 pg/kg/d, SC): one from day 1 to day 18 and two from day 1 to day 21. One monkey was treated with the combination of rhIL-6 plus rhIL-3 (10 pg/kg/d each) from day 1 to day 32; two monkeys with the combination of rhIL-6 plus rhG-CSF (10 pg/kg/d, SC each) from day 1 to day 17 and day 1 to day 25, respectively; one monkey with the combination of rhIL-6 plus rcGM-CSF (10 kg/kg/d, each) from day 1 to day 21; and one monkey with the combination of rhIL-6 plus rhLIF (10 pg/kg/d, SC each) from day 1 to day 18. rhLIF was also administered alone (10 pg/kg/d) to two monkeys for 14 and 18 days, respectively. TBI was administered to nine primates using 10 MV x-rays of a linear accelerator (Siemens Mevatron 74) by two antero-posterior opposed fields. The narcotized animals were placed and fixed immediately under an acrylic plate with a thickness of 2 cm to avoid dose build-up. The eyes were shielded by small blocks to reduce the risk of cataract formation. Dose distribution was checked by in vivo measurements with thermoluminescent dosimeters (TLDs). The results are summarized in Table 1 . Because of the small thickness of the monkey's thorax (diameter, 7 to 8 cm), there are no large dose variations. Total dose values are therefore calculated by averaging entrance and exit doses, reflecting the doses within the body section, too.
Treatment schedule. Six of the nine animals received additional treatment with rhIL-6 SC: one at a dose of 10 pg/kg/d of Peg-rhIL-6, three at a dose of 10 pg/kg/d of Peg-rhIL-6, and two at a dose of 100 pg/kg/d of Peg-rhIL-6. rhIL-6 was administered from day 0 until day 28 post irradiation, or from day + 1 until day 28 post irradiation.
Assays for detecting antibodies directed against rhIL-6 in monkey serum were performed as described in detail by Mayer et al.13
RESULTS
Effect of rhiL-6 on platelet counts. In all three monkeys receiving rhIL-6 alone, the platelet counts (per microliter) increased significantly (animal no. 1, from 254,000 to 756,000; animal no. 2, from 513,000 to 786,000; and animal no. 3 from 276,000 to 592,000 (Figs 1 and 2 ). rhIL-6 did not significantly change the numbers of PB neutrophils, eosinophils, basophils, lymphocytes, or erythrocytes (data not shown).
Effect of rhiL-6 in combination with rhIL-3 on blood cells. The data of the PB platelets in animal no. 4, receiving both rhIL-6 and rhIL-3, are shown in Fig 1. This combination led to an increase in PB platelets from 362,OOO/pL to a maximum of 675,OOO/pL on day 10 of the treatment (Figs 1  and 2 ). This increase is equivalent to the increase of platelets seen with rhIL-6 alone and did not show an additive or synergistic effect.
The eosinophil counts increased significantly from 214/ pL to a maximum of 4,089/pL. There was also a significant increase in basophil counts from initially 0 to maximal numbers of 2,240 cells/pL. rhIL-3 alone at dosages of 10 pg/kg/d and 100 pg/kg/d SC administered for 14 days each had no effect on the number of blood platelets (data not shown).
Effect of rhIL-6 in combination with rhG-CSF on blood cells. Two monkeys were treated with the combination of rhIL-6 and rhG-CSF, 10 pg/kg/d each SC, over a period of 17 days in animal no. 5 and 25 days in animal no. 6. In animal no. 5, the PB platelet counts (per microliter) increased from 252,000 to a maximum of 638,000. In animal no. 6 from 342,000 to a maximum of 1,104,000 (Figs 1 and Neutrophils increased from 1,624/ pL (day 1) to maximal counts of 33,947/pL (animal no. 5) and from 5,06O/pL to 52,809/pL (animal no. 6).
Lymphocytes increased from 3,864/pL on day 1 to a maximum of 9,693/pL in animal no. 5 and from 5,500/ pL to a maximum of 16,628/pL in animal no. 6.
There was no significant change in the counts of the other PB cells.
Effect of rhIL-6 in combination with rcGM-CSF on blood cells. Animal no. 7 was treated with the combination of rhIL-6 and rcGM-CSF from day 1 to day 21. Platelets increased from 334,OOO/pL initially to a maximum of 538,OOO/pL (Figs 1 and 2) . Neutrophils increased significantly from 2,652/pL to maximum counts of 34,286/ pL and eosinophils increased from 156 cells/pL to 4,704/pL. In this animal, the PB lymphocytes increased from 12,48O/ pL to 16,8OO/pL.
There was no significant change in the basophil or monocyte counts.
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Effects of rhIL-6 in combination with rhLIFon thrombopoiesis. rhLIF was first tested alone on its activity on thrombopoiesis in two animals. As shown in Fig 3, rhLIF (10 pg/kg/d SC) was capable of increasing the PB platelet counts up to twofold. One monkey received the combination of rhIL-6 and rhLIF (10 pg/kg/d SC, each) (Fig 3) . There was no synergistic or additive increase in PB platelet counts. The effects of the combination were similar to the activities seen when rhIL-6 was used alone (Fig 1) .
The platelet counts before any treatment and the maximum platelet counts reached with each combination used are summarized in Fig 2. The number of megakaryocytes per 1,000 mononuclear BM cells was approximately 1 to 1.5 in the control monkeys as analyzed microscopically on regular glass slides. rhIL-6 and rhLIF were not able to increase the number of megakaryocytes. However, the DNA ploidy distribution of megakaryocytes derived from monkeys treated with rhIL-6 or rhLIF showed an increase in higher ploidy cells (> 16 N) (Table Effects of rhIL-6 and rhLIF on BM megakaryocytes. Effects of rhZL-6 in animals receiving TBI. Nine animals received TBI of 3.8 Gy. One of the nine monkeys was treated with 10 kg/kg/d of rhIL-6 from day 0 to day 28 post irradiation, three were treated with 10 pg/kg/d Peg-rhIL-6 SC from day 1 to day 28 post irradiation, and two were treated with 100 kg/kg/d of Peg-rhIL-6 from day 1 to day 28 post irradiation. As shown in Fig 4, rhIL-6 or Peg-rhIL-6 (n = 3) at doses of 10 kg/kg/d neither prevented the platelet nadir nor fastened the recovery of platelet counts post irradiation. However, when Peg-rhIL-6 was used at a dose of 100 pg/kg/d (n = 2), the animals experienced an earlier nadir (day 12 instead of day 15 in control animals), but the degree of thrombocytopenia (mean platelet count, 71,000 v 39,000) was substantially lower and the time of thrombocytopenia was shorter ( 3 v 5 days) (Fig 4) .
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No adverse events were seen in any animals treated with rhIL-6. One monkey was retreated 1 month after the discontinuation of rhIL-6 with rhIL-6 (10 pg/kg/d) for 2 weeks. This animal did not show any increase of platelets anymore (data not . We had serum samples drawn before rhIL-6 treatment and weekly during rhIL-6 treatment in five animals. In four of the five animals, we could detect anti-rhIL-6 antibodies at a titer of between 1500 and 1:2,000 after 2 weeks of rhIL-6 treatment in one animal after 3 weeks of rhIL-6 treatment.
DISCUSSION
Our data in primates show that in vivo administration of rhIL-6 increases platelet production, as judged by PB platelet counts. The platelet counts increased twofold to threefold and reached a maximum by day 10 of treatment when rhIL-6 was administered alone. rhIL-6 had no effects on cell lineages other than platelets. rhLIF (recently reported to increase in vivo platelet counts in mice)I4 also induced thrombocytosis in the animals studied, although its effect was inferior to rhIL-6. Both the application of rhIL-6 and of rhLIF did not result in adverse events. The effect of rhIL-6 on platelet counts could not be further increased by combinations of rhIL-6 with rhLIF, rhG-CSF, rcGM-CSF, or rhIL-3, respectively. The lack of any synergy or additive effect of the combination of rhIL-6 and rhLIF was unexpected. However, this does not exclude that suboptimal dosages of rhIL-6 and rhLIF might show synergism. G-CSF was tested in this study because of its similarities in structure with rhIL-6. However, G-CSF showed no megakaryocyte colony-stimulating activity in vitroz0 and did not increase PB platelets in various clinical trials. '6 The lack of synergistic action of rhIL-6 with rcGM-CSF and, particularly, rhIL-3 was also unexpected. Both IL-3 and, to a lesser extent, GM-CSF have been shown to induce formation of megakaryocyte colonies in and current evidence indicates that the effects are mediated by direct effects of these cytokines on megakaryopoietic progenitor cells. The lack of action on thrombopoiesis of human IL-3 in primates might be attributable, in part, to its species specificity.a In clinical trials, human IL-3 has been shown to be effective on megakaryopoiesi~.~~ In addition, IL-6 enhances IL-3-dependent blast cell colony formation by using CD34+ BM cells in vitro.6 From this data, one might expect synergistic effects from the combination of rhIL-6 with rhIL-3 on other hematopoietic cell lineages, eg, myeloid cells. However, in our experiments, such synergism was not observed. The increases in eosinophils and basophils are identical to increases induced by rhIL-3 alone, documenting the in vivo activity of rhIL-3 in monkeys.
The combination of rhIL-6 with rcGM-CSF also did not show additional effects on PB cell counts (except platelets) compared with the results seen by administration of rcGM-CSF alone ( Table 2 ). There was a threefold increase in PB lymphocytes in the animals receiving the combination of rhIL-6 with rhG-CSF. The phenotype of the lymphocytes during rhIL-6 administration showed no changes in the percentages of subpopulations during treatment.
rhIL-6, as well as rhLIF, induced a right shift in megakaryocyte DNA ploidy, as studied by two-color FACS analysis. These data, as well as the observation that the absolute numbers of megakaryocytes in BM did not increase, indicate that rhIL-6 and rhLIF act as "thrombopoietin-like" activities, stimulating the maturation of megakaryocytes and finally resulting in platelet release.
A major problem of using human IL-6 in monkeys is that the long-term information is limited because all animals developed antibodies against rhIL-6 starting between day 14 and day 21 of treatment. This has also been reported by other investigators using human IL-6 in monkeys.13 Nevertheless, the results obtained within the first 2 weeks of rhIL-6 treatment are most likely not influenced by antirhIL-6 antibodies and therefore are valuable for the shortterm effects of rhIL-6 in vivo.
Because rhIL-6 was capable of inducing an increase of platelets in all animals treated, it was obviously necessary to test whether rhIL-6 might also protect the animals from thrombocytopenia or shorten the time of thrombocytopenia after myelotoxic therapies such as irradiation or chemotherapy. Due to the lack of synergy with other growth factors in healthy animals, we only used rhIL-6 alone in irradiated monkeys. At the dose of 10 pg/kg/d, rhIL-6 or Peg-rhIL-6 had no effect on the severety of thrombocytopenia and the time of platelet recovery. However, when Peg-rhIL-6 was used at a dose of 100 pg/kg/d, the mean of the nadir occurred earlier (day 12 v day 15) and was not as low as in control animals (71,000 v 39,000). In addition, the time interval of platelet numbers below 100,000 was shorter (3 v 5 days). These data show that post radiation recovery of thrombopoiesis is only accelerated by high doses of PegrhIL-6. This is supported by data in mice in which only ultra-high dosages of rhIL-6 (1,000 pg/kg/d) had minor effects on the recovery of platelets after TBI with 6.5 Gy.l0 These data suggest that IL-6 represents a late-acting factor in megakaryopoiesis, displaying "thrombopoietin'like" activity and no megakaryocyte colony-stimulating activity. Only in high dosages did rhIL-6 have some effects. The megakaryocyte progenitor cell recovery may not be augmented by rhIL-6 application. A megakaryocyte-CSF such as the activity present in plasma from patients with thromb~c y t o p e n i a~~~~l might be more potent in fastening platelet recovery postirradiation. Alternatively, irradiation-induced damage to BM microenvironment prevents rhIL-&induced elaboration of other cytokines from accessory cells. Indeed, rhIL-6 and IL-la in concert promote de novo elaboration of IL-3 in vitro.32
It remains questionable whether these doses of rhIL-6 might be realistic for clinical use. Further experiments in this direction have to be performed.
